- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07939893
Brief Title: Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA
EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL
Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Zeenat Usman, MS obstetrics and Gyanecology
- Telefonnummer: +923315333910
- E-post: usmanbut2@gmail.com
Studer Kontakt Backup
- Navn: Quratulain Assosciate Professor, FCPS - Obstetrics and Gynaecol
- Telefonnummer: +92335587882
- E-post: qurratulain_saeed@yahoo.com
Studiesteder
-
-
Islamabad
-
Islamabad, Islamabad, Pakistan, 04485
- Pakistan Institute of Medical Sciences (PIMS)
-
Ta kontakt med:
- Zeenat Usman, MS Obstetrics and gyanecology
- Telefonnummer: +923315333910
- E-post: qurratulain_saeed@yahoo.com
-
Ta kontakt med:
- Quratulain Associate Professor, FCPS - Obstetrics and Gynaecol
- Telefonnummer: +92335587882
- E-post: qurratulain_saeed@yahoo.com
-
Hovedetterforsker:
- Zeenat Usman, MS obstetrics and gyane
-
Underetterforsker:
- Quratulain Saeed, FCPS - Obstetrics and Gynaecol
-
Underetterforsker:
- Tooba Batool
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women aged 18 years or older.
- Women scheduled to undergo an eligible transcervical uterine procedure under total intravenous anaesthesia (TIVA).
- Women with stable haemodynamic condition before surgery.
Exclusion Criteria:
- Known allergy or hypersensitivity to lidocaine or other planned local anaesthetic.
- Significant hepatic disease affecting local anaesthetic metabolism.
- Chronic opioid use or chronic pain requiring regular analgesic therapy.
- Major intraoperative complication requiring deviation from the standardized anaesthetic or surgical protocol.
- Patients requiring emergency surgery where informed consent or standardized study procedures cannot safely be completed.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Paracervical Block Plus Standard Analgesia
Participants will receive a standardized paracervical block using lidocaine in addition to standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures. Postoperative pain scores and analgesic requirements will be assessed and compared with the control group. |
A standardized paracervical block will be administered after induction of total intravenous anesthesia (TIVA) and before uterine manipulation. The technique will use 2% lidocaine without adrenaline, with 1 mL injected at each of four cervical positions (2, 4, 8, and 10 o'clock), for a total volume of 4 mL (80 mg lidocaine). Aspiration will be performed before and during injection to reduce the risk of intravascular administration. The block will be given in addition to standard TIVA and perioperative analgesia for eligible transcervical uterine procedures. |
|
Ingen inngripen: Standard Analgesia Alone
Participants will receive standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures without a paracervical block. Postoperative pain scores and analgesic requirements will be assessed and compared with the intervention group. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative Pain Score (0-10 Visual Analogue Scale [VAS] Score)
Tidsramme: From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.
|
Postoperative pain intensity will be measured using a 0-10 Visual Analogue Scale (VAS), with 0 representing no pain and 10 representing the worst imaginable pain. The VAS score will be recorded for each participant at recovery room arrival (when awake and able to communicate), 30 minutes, 1 hour, 2 hours, and 4 hours after the procedure, where feasible. The mean or median postoperative pain scores will be compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone. |
From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Requiring Rescue Analgesia (%)
Tidsramme: From completion of the procedure until 4 hours post-procedure.
|
The proportion of participants requiring additional rescue analgesia for postoperative pain despite receiving standard perioperative analgesia will be recorded. Rescue analgesia requirement will be assessed as a binary outcome (Yes/No) using the study Case Report Form (CRF). The percentage of participants requiring rescue analgesia will be compared between the intervention and control groups.Control group is the one receiving standard analgesia that is only TIVA and case group is standard analgesia that is TIVA and paracervical block group |
From completion of the procedure until 4 hours post-procedure.
|
|
Time to First Rescue Analgesia (Minutes)
Tidsramme: From completion of the procedure until 4 hours post-procedure
|
Time to first rescue analgesia will be measured in minutes from completion of the transcervical uterine procedure to administration of the first rescue analgesic. The time of administration will be documented using the medication administration record and structured Case Report Form (CRF), and compared between the two study groups. |
From completion of the procedure until 4 hours post-procedure
|
|
Total Postoperative Rescue Analgesic Requirement (Drug-Specific Dose)
Tidsramme: From completion of the procedure until 4 hours post-procedure.
|
The total dose of additional rescue analgesic medication administered to each participant for postoperative pain will be recorded using the medication administration record and structured Case Report Form (CRF). The drug name, individual dose and total dose administered during the postoperative observation period will be documented and compared between the two study groups. Results will be expressed in the appropriate drug-specific dose units (e.g., milligrams). |
From completion of the procedure until 4 hours post-procedure.
|
|
Patient Satisfaction Score with Postoperative Pain Management (5-Point Likert Scale)
Tidsramme: At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
|
Participant satisfaction with postoperative pain management will be assessed using a predefined 5-point Likert scale recorded on the structured Case Report Form (CRF). The scale ranges from 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), to 5 (very satisfied). Individual satisfaction scores will be recorded and compared between the two study groups. |
At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
|
|
Time to First Mobilization (Minutes)
Tidsramme: From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
|
Time to first mobilization will be measured in minutes from completion of the transcervical uterine procedure to the participant's first mobilization. The time will be recorded using the structured Case Report Form (CRF) and compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone. |
From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
|
|
Incidence of Postoperative Nausea and Vomiting (Number and Percentage of Participants)
Tidsramme: From arrival in the recovery area until 4 hours after completion of the procedure.
|
The incidence of postoperative nausea and vomiting will be assessed by recording the presence or absence of nausea and vomiting (Yes/No) using the structured Case Report Form (CRF). The requirement for rescue antiemetic medication will also be documented as Yes or No. Results will be expressed as the number and percentage of participants experiencing nausea and vomiting in each study group. |
From arrival in the recovery area until 4 hours after completion of the procedure.
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Zeenat Usman, MS obstetrics and Gyanecology, SZABMU,PIMS
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Postoperative komplikasjoner
- Patologiske prosesser
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Smerter, postoperativt
- Organiske kjemikalier
- Anilider
- Amides
- Anilinforbindelser
- Aminer
- Acetanilider
- Anestesi og smertestillende
- Anestesi
- Lidokain
- Anestesi, Obstetrikk
Andre studie-ID-numre
- F-5-2/2024(ERRC)30th-PIMS
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data collected during this study will not be shared publicly or made available to external researchers. Data will be used by the study investigators for the purposes of the approved research. Participant confidentiality will be maintained in accordance with institutional ethical requirements.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .